156 related articles for article (PubMed ID: 8271535)
1. Thrombolytic activity of a novel modified tissue-type plasminogen activator, YM866, in a canine model of coronary artery thrombosis.
Kawasaki T; Katoh M; Kaku S; Gushima H; Takenaka T; Yui Y; Kawai C
Jpn J Pharmacol; 1993 Sep; 63(1):9-16. PubMed ID: 8271535
[TBL] [Abstract][Full Text] [Related]
2. Thrombolysis with intracoronary administration of YM866, a novel modified tissue-type plasminogen activator, in a canine model of coronary artery thrombosis.
Kawasaki T; Katoh M; Kaku S; Gushima H; Takenaka T; Yui Y; Kawai C
Jpn J Pharmacol; 1993 Nov; 63(3):319-25. PubMed ID: 8107325
[TBL] [Abstract][Full Text] [Related]
3. Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi.
Suzuki S; Saito M; Suzuki N; Kato H; Nagaoka N; Yoshitake S; Mizuo H; Yuzuriha T; Yui Y; Kawai C
J Cardiovasc Pharmacol; 1991 May; 17(5):738-46. PubMed ID: 1713988
[TBL] [Abstract][Full Text] [Related]
4. YM866, a novel modified tissue-type plasminogen activator, affects left ventricular function and myocardial infarct development in dogs with coronary artery thrombi.
Suzuki M; Funatsu T; Tanaka H; Usuda S
Jpn J Pharmacol; 1998 Jul; 77(3):177-83. PubMed ID: 9717764
[TBL] [Abstract][Full Text] [Related]
5. Experimental model of carotid artery thrombosis in rats and the thrombolytic activity of YM866, a novel modified tissue-type plasminogen activator.
Kawasaki T; Kawamura S; Katoh S; Takenaka T
Jpn J Pharmacol; 1993 Oct; 63(2):135-42. PubMed ID: 8283822
[TBL] [Abstract][Full Text] [Related]
6. Thrombolytic activity of YM866, a novel modified tissue-type plasminogen activator, in a photochemically induced platelet-rich thrombosis model.
Kawasaki T; Kaku S; Takenaka T; Yanagi K; Ohshima N
J Cardiovasc Pharmacol; 1994 Jun; 23(6):884-9. PubMed ID: 7523779
[TBL] [Abstract][Full Text] [Related]
7. Single bolus administration of recombinant tissue plasminogen activator: effects on infarct related vessel patency, microvascular perfusion, and microvascular reocclusion in a canine model of thrombotic occlusion/reperfusion.
Longridge DJ; Follenfant MJ; Ford AJ
Cardiovasc Res; 1991 Mar; 25(3):184-91. PubMed ID: 1903080
[TBL] [Abstract][Full Text] [Related]
8. Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
Rapold HJ; Wu ZM; Stassen T; Van de Werf F; Collen D
Blood; 1990 Oct; 76(8):1558-63. PubMed ID: 2119830
[TBL] [Abstract][Full Text] [Related]
9. Intracoronary infusion of E6010 has more potent thrombolytic activity than tissue plasminogen activator (t-PA) in dogs: a higher plasma level of E6010 than t-PA causes potent thrombolytic activity.
Suzuki S; Saito M; Suzuki N; Kato H; Nagaoka N; Yoshitake S; Yui Y; Kawai C
J Cardiovasc Pharmacol; 1993 Dec; 22(6):834-40. PubMed ID: 7509901
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of a mutant tissue-type plasminogen activator, YM866, with a tissue-type plasminogen activator in a canine model of femoral arterial thrombosis.
Kawasaki T; Kaku S; Sakai Y; Takenaka T
J Pharm Pharmacol; 1996 Oct; 48(10):1041-8. PubMed ID: 8953506
[TBL] [Abstract][Full Text] [Related]
11. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
[TBL] [Abstract][Full Text] [Related]
12. Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis.
Martin U; Fischer S; Sponer G
J Am Coll Cardiol; 1993 Sep; 22(3):914-20. PubMed ID: 8354832
[TBL] [Abstract][Full Text] [Related]
13. Comparative studies of thrombolysis with single-chain and two-chain recombinant tissue-type plasminogen activators in canine coronary thrombosis.
Yokoyama M; Ichikawa Y; Yatani A; Matsui K; Nakahara H; Kaneko M; Sakurama T; Ueshima S; Matsuo O
J Cardiovasc Pharmacol; 1996 Oct; 28(4):571-5. PubMed ID: 8891884
[TBL] [Abstract][Full Text] [Related]
14. Double bolus administration of the novel recombinant plasminogen activator BM 06.022 improves coronary blood flow after reperfusion in a canine model of coronary thrombosis.
Martin U; Sponer G; König R; Smolarz A; Meyer-Sabellek W; Strein K
Blood Coagul Fibrinolysis; 1992 Apr; 3(2):139-47. PubMed ID: 1606285
[TBL] [Abstract][Full Text] [Related]
15. Newer thrombolytic agents.
Verstraete M
Ann Acad Med Singap; 1999 May; 28(3):424-33. PubMed ID: 10575530
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis.
Martin U; Sponer G; Strein K
J Am Coll Cardiol; 1992 Feb; 19(2):433-40. PubMed ID: 1732372
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis.
Cambier P; van de Werf F; Larsen GR; Collen D
J Cardiovasc Pharmacol; 1988 Apr; 11(4):468-72. PubMed ID: 2453751
[TBL] [Abstract][Full Text] [Related]
18. Thrombolysis of canine femoral artery thrombus by a novel modified tissue-type plasminogen activator (E6010).
Suzuki N; Suzuki S; Nagaoka N; Mizuo H; Yuzuriha T; Yoshitake S; Kanmatuse K
Jpn J Pharmacol; 1994 Jul; 65(3):257-63. PubMed ID: 7799526
[TBL] [Abstract][Full Text] [Related]
19. Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model.
Lu HR; Lijnen HR; Stassen JM; Collen D
Blood; 1991 Jul; 78(1):125-31. PubMed ID: 1906351
[TBL] [Abstract][Full Text] [Related]
20. Ventricular function and cardiac hypertrophy after coronary thrombolysis with tissue-type plasminogen activator (t-PA) in dogs with coronary artery thrombi.
Suzuki M; Asano H; Kimoto A; Tanaka H; Usuda S
J Pharm Pharmacol; 2000 Aug; 52(8):969-76. PubMed ID: 11007068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
